Keywords: Pfizer, Vfend, Eraxis, Fungal infections, Ph III

Inconclusive Ph III results for Pfizer’s Vfend and Eraxis combo in fungal infections

Article | 03 October 2011

Print This

There was disappointing news for global drugs behemoth Pfizer (NYSE: PFE) last Friday, when the company reported top-line results from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in